The Readout Loud

Latest Episodes:

345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies Mar 13, 2025

Show notes

We bring on our colleague Sarah Owermohle to discuss the White House's sudden move to withdraw the nomination of Dave Weldon as its pick to run the CDC just hours before Weldon's confirmation hearing. It's also the five-year anniversary of the Covid-19 pandemic. We chat with Princeton political scientist Frances Lee about a new book she co-authored that offers an unflinching assessment of the U.S. policy responses to the pandemic and raises some provocative questions about what went wrong.

344: Trump's FDA commissioner nominee takes the hot seat Mar 06, 2025

Show notes

Will Marty Makary be confirmed as the next commissioner of the Food and Drug Administration? Will he bring back employees laid off by DOGE? And what did he get wrong during his confirmation hearing? We discuss all that and more during this week's special episode.

343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs Feb 27, 2025

Show notes

It’s a STAT reporter two-fer guest episode. First, Lizzy Lawrence joins from D.C. to dish on the upheaval and drama taking place at the FDA. Then, we chat with Jason Mast about Bluebird Bio, its fire sale to private equity and what lies ahead for the unsettled world of genetic medicines. Before those discussions, Allison provides some insight into the “new kids” on the biotech VC block.

342: FDA cuts, zombie biotechs, and too much weight loss? Feb 20, 2025

Show notes

Mizuho analyst Jared Holz joins to discuss Adam's column on biotech's dark period. We also talk about Elaine's latest article on the push for greater and greater weight loss from obesity drugs, along with developments at Solid Biosciences and federal job cuts.

341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers Feb 13, 2025

Show notes

We bring on biotech reporter Jonathan Wosen to discuss the NIH's decision to dramatically cut funding for overhead costs paid to research institutions and the potential implications for U.S. biomedical innovation. We also chat with health tech reporter Brittany Trang about the claims that two drug developers, Absci and Generate:Biomedicines, have made about the capabilities of their artificial intelligence technologies, and why some experts are skeptical.

340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug Feb 06, 2025

Show notes

We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.'s nomination to be HHS secretary, the latest pharma earnings, and the approval of a non-opioid pain drug from Vertex Pharmaceuticals.

339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad Jan 30, 2025

Show notes

Our colleague Rachel Cohrs Zhang joins us to break down RFK Jr.’s confirmation hearings, including some contentious questions about vaccines and autism from Sens. Bill Cassidy (R-La.) and Bernie Sanders (I-Vt.). But first, we chat about Akero Therapeutics and the results reported this week from a study of its experimental drug that showed, for the first time, reversal of cirrhosis in patients with severe MASH. We critique that Hims & Hers commercial. And lastly, we talk about a new fund from biotech VC Curie.Bio and the money it’s invested in a still-stealthy gene therapy company trying to tackle ALS.

338: Chinese biotechs, a WHO departure, and post-JPM thoughts Jan 23, 2025

Show notes

We go over our closing thoughts from the J.P. Morgan Healthcare Conference, including the chatter around Chinese drugs and a surprise run-in with a past cohost. Then, STAT's infectious disease reporter Helen Branswell joins us to explain the implications of Trump's decision to pull the U.S. out of the WHO.

337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss Jan 15, 2025

Show notes

We're live at the J.P Morgan Healthcare Conference in San Francisco! We bring on Eli Lilly CEO Dave Ricks for a wide-ranging conversation about his views on the incoming Trump administration, the effects of Medicare's drug price negotiation, Lilly's recent disappointing guidance, pricing of the company's obesity medication Zepbound, and more. We also discuss the latest news from the J.P. Morgan conference, including M&A deals, licensing of drugs from China, and the broader sentiment in the industry.

336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study Jan 09, 2025

Show notes

We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected